Huiping Jiang began her career as Director of Regulatory Affairs at Boehringer Ingelheim in 2013 and then as Vice President of Regulatory Affairs at Epizyme in Cambridge, MA starting in 2019. While at Epizyme, she then became Senior Vice President and Head of Regulatory Affairs until 2021. During her time at Epizyme, she was responsible for leading the regulatory strategies, submissions and approvals for the drugs Tazverik and Cyltezo. Finally, prior to joining Onxeo, she served as Interim President at Qx Therapeutics from 2021.
Huiping Jiang has a Ph.D. in cell and molecular biology from Clarkson University and then participated in a post-doctoral research program on genetic engineering and molecular genetics in signal transduction